We know that they have enough cash to get them into the 1st half of 2012 without any additional milestone payments. We are eligible for $6 million milestone payments for each if they go to phase 3 for colorectal and ovarian cancer. We should know how the colorectal cancer study is going in 2010 and the ovarian study is due in 2011.
In addition to those payments, we are also due a payment that is "north" of the payments due for phase 3 upon submission of NDA for BCC which hopefully will happen early next year. Passeri is the one who stated the milestone payment will be "north" of the phase 3 payments and what that means, I haven't got a clue.
The last milestone payment that is due will be from Debiopharm when they treat the 5th patient under phase 1 of 0932. We haven't gotten word whether or not the study has even commenced yet and we don't know how much that will be but it should be a few million anyway. Assuming those payments come in, then the company should have enough cash to then carry them well into 2013 without the need for an additional dilution IMO. They may still do another offering if the pricing is right but at least they won't have to unless it is in their best interest.
The big thing for us will come in 2011 when they file the NDA submission for BCC. Assuming that happens the other things will fall into place because we should get decent money and additional coverage which will increase the stock price substantially IMO. If we don't get the NDA submission next year, we are in trouble and we will fall substantially.
GLTA and let's hope things are progressing as we hope. Hopefully in addition to the above possible catalysts, we get positive word out of the blue regarding any of the other current phase 1 and 2 trials underway. This will be an interesting year to be a Curis shareholder.